Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q9Y2D2
UPID:
S35A3_HUMAN
Alternative names:
Golgi UDP-GlcNAc transporter; Solute carrier family 35 member A3
Alternative UPACC:
Q9Y2D2; A8K3F8; D3DT54; Q68CR2; Q9BSB7
Background:
The UDP-N-acetylglucosamine transporter, also known as Solute carrier family 35 member A3 (SLC35A3), plays a crucial role in cellular function by transporting UDP-GlcNAc into the Golgi apparatus. This process is essential for the synthesis of complex N-glycans and keratan sulfate, contributing to cell surface glycosylation.
Therapeutic significance:
SLC35A3's involvement in the disease 'Arthrogryposis, impaired intellectual development, and seizures' highlights its potential as a therapeutic target. The disease's association with altered glycosylation patterns suggests that modulating SLC35A3 activity could offer new avenues for treatment.